Brought to you by 
Enzon gets rights to Elan's Abelcet for $370mm
Oct 2002
Executive Summary
As part of its plan to divest certain assets, Elan Corp. has exclusively licensed Enzon (therapeutics for life-threatening diseases) US, Canadian, and Japanese rights to its antifungal Abelcet (amphotericin B lipid complex injection).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing-Licensing
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Enzon gets rights to Elan's Abelcet for $370mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice